TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04231708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine + Hydrocortisone
Description: Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine + Hydrocortisone
Description: Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: 10Hz rTMS over the left dlPFC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: 10Hz rTMS over the left dlPFC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose (inside capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose (inside capsule)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: inactive stimulation over the left dlPFC

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: inactive stimulation over the left dlPFC
Study: NCT04953390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo hearing aid
Description: Commercially available hearing aid with three different microphone settings: DIR1, DIR2, and DIR3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak hearing aid with multiple directionality settings, adjustable via a mobile app
Description: Commercially available hearing aid with multiple directionality settings which will be adjustable by user via a mobile app during a home trial period.
Study: NCT05698238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA9hu-1
Description: Humanized monoclonal antibody to human carbonic anhydrase IX
Study: NCT05554068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
Study: NCT06121154

Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F questionnaire
Description: The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARC-F questionnaire
Description: The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait speed
Description: Low gait speed was defined as walking below than 0.8 meters per second.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait speed
Description: Low gait speed was defined as walking below than 0.8 meters per second.

Intervention type: DIAGNOSTIC_TEST
Intervention: The chair rise test
Description: the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds
Study: NCT05442333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection with safety margin
Description: • The patients with preoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection with safety margin
Description: • The patients with preoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.
Study: NCT05170256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
Study: NCT06121154

Intervention type: DIAGNOSTIC_TEST
Intervention: The chair rise test
Description: the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: Grip strength
Description: Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females

Intervention type: DIAGNOSTIC_TEST
Intervention: Grip strength
Description: Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual analog scale
Description: The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual analog scale
Description: The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)
Study: NCT05932693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-3, 2.0%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 2.0%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (menthol, 0.05%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.05%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (menthol, 0.1%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.1%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (menthol, 0.5%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.5%.
Study: NCT05049759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Confident, Active and Happy Youth
Description: The three target goals of the intervention (confident, active and happy) link closely to the core symptoms of internalizing disorders. Thus, a core symptom of anxiety is a lack of confidence in one's ability to cope with a given fearful situation. The ensuing behavioral reaction is avoidance of the situation and/or enduring it with excessive discomfort. Similarly, a core symptom of a depressive disorder is lowered mood. Regarding both depression and anxiety, both disorders are associated with less physical activity, and low levels of physical activity conversely help maintain the disorders. As such, the aim is to alleviate symptoms and supplement ongoing treatment in CAMHS.
Study: NCT05047055

Intervention type: DRUG
Intervention: Isoniazid
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.

Intervention type: DRUG
Intervention: Rifampicin
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.

Intervention type: DRUG
Intervention: Pyrazinamide
Description: Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.

Intervention type: DRUG
Intervention: Ethambutol
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.

Intervention type: DRUG
Intervention: Moxifloxacin
Description: Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
Study: NCT05736341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
Study: NCT05596175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Rehab
Description: A 12-month healthcare-delivered lifestyle intervention involving exercise, nutritional support and optimisation of AF-related clinical risk factors.
Study: NCT06008574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmDTx-PCSP
Description: Step-by-step program modules including meditation training and other activities relevant for people living with cancer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AmDTx-2048
Description: Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
Study: NCT05932693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (menthol, 1.0%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 1.0%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (menthol, 2.0%)
Description: Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 2.0%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-23, 0.05%)
Description: Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.05%.
Study: NCT06490250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin Exercise
Description: The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
Study: NCT06029309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15
Study: NCT06579066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Blend Capsule
Description: Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Patients will administer (activated charcoal) Charclone® 1000MG Tablet three times daily orally along with the standard care of therapy for duration of 4 weeks.
Study: NCT05141071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 5mg Tab
Description: Ivabradine will be administrated enterally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of saline will be administrated enterally
Study: NCT05213559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wheat biscuit enriched with plant proteins
Description: Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: common wheat biscuit
Description: Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
Study: NCT05824312

Intervention type: DRUG
Intervention: Tyrosine kinase inhibitor drugs.
Description: TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
Study: NCT04502758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture TMS Therapy System w/Theta Burst Stimulation
Description: During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
Study: NCT05932693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-23, 0.1%)
Description: Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.1%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-23, 0.5%)
Description: Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.5%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-23, 1.0%)
Description: Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 1.0%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-23, 2.0%)
Description: Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 2.0%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid coolant (WS-23, 4.0%)
Description: Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 4.0%.
Study: NCT05423925

Intervention type: PROCEDURE
Intervention: Bipolar hysteroscopic myomectomy
Description: Bipolar hysteroscopic myomectomy.

Intervention type: PROCEDURE
Intervention: Monopolar hysteroscopic myomectomy
Description: Monopolar hysteroscopic myomectomy
Study: NCT04219540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-B (SUBLOCADETM)
Description: XR-B (SUBLOCADETM) contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. Following induction and dose adjustment with sublingual buprenorphine, the recommended starting dose is 300 mg monthly for the first two months followed by a maintenance dose of 100 mg monthly thereafter. XR-B is administered monthly only by subcutaneous injection in the abdominal region. Study clinical staff will have flexibility to continue the 300mg dose for greater than 2 months, or use the 100mg dose for initial induction, if the participant's opioid use history or clinical status at the time of dosing support these decisions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX
Description: XR-NTX (Vivitrol®) produces a 30-day mu opioid receptor antagonist blockade Induction procedures require detoxification off opioids (5-7 days since last opioid use), a negative opioid urine toxicology, negative self-report of any recent opioid use, and a naloxone challenge. The naloxone challenge consists of 0.4-0.8mg of IV/SC/IM naloxone followed by the observation of no opioid withdrawal symptoms, or the use of oral naltrexone (12.5-25mg) followed by 1-2 hours of observation. XR-NTX is then delivered as a 380mg (4cc) intramuscular injection to the upper outer gluteus (buttock). Study interventions are FDA-approved, used in accordance with FDA-labeling and will be administered by a study clinician
Study: NCT05724979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZP-binding
Description: The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region
Study: NCT04502758

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MagVenture TMS Therapy System w/Theta Burst Stimulation
Description: During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
Study: NCT05519579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab 28ug/day continuous infusion for 4 weeks
Study: NCT05471648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection
Description: Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta (EU origin) 420 mg in 14 mL Injection
Description: Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta (US origin) 420 mg in 14 mL Injection
Description: Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
Study: NCT04886882

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: solution containing 0.9 % sodium chlorine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham comparator
Description: vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental drug 1
Description: A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental drug 2
Description: A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Centella asiatica
Description: A cream containing Centella asiatica
Study: NCT04704518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4%
Description: Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
Description: Topical ophthalmic administration of one drop of Thealoz® Duo QID.
Study: NCT04928820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT